184 related articles for article (PubMed ID: 2294224)
1. Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study.
Bukowski RM; Goodman P; Crawford ED; Sergi JS; Redman BG; Whitehead RP
J Natl Cancer Inst; 1990 Jan; 82(2):143-6. PubMed ID: 2294224
[TBL] [Abstract][Full Text] [Related]
2. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
3. Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
Dutcher JP; Fisher RI; Weiss G; Aronson F; Margolin K; Louie A; Mier J; Caliendo G; Sosman JA; Eckardt JR; Ernest ML; Doroshow J; Atkins M
Cancer J Sci Am; 1997; 3(3):157-62. PubMed ID: 9161781
[TBL] [Abstract][Full Text] [Related]
4. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: a single-center phase II study.
Geertsen PF; Hermann GG; von der Maase H; Steven K
J Clin Oncol; 1992 May; 10(5):753-9. PubMed ID: 1569448
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.
Whitehead RP; Wolf MK; Solanki DL; Hemstreet GP; Benedetto P; Richman SP; Flanigan RC; Crawford ED
J Immunother Emphasis Tumor Immunol; 1995 Aug; 18(2):104-14. PubMed ID: 8574465
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study.
Negrier S; Philip T; Stoter G; Fossa SD; Janssen S; Iacone A; Cleton FS; Eremin O; Israel L; Jasmin C
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S21-8. PubMed ID: 2697575
[TBL] [Abstract][Full Text] [Related]
9. Recombinant interleukin-2 in metastatic renal cell carcinoma--a European multicentre phase II study.
von der Maase H; Geertsen P; Thatcher N; Jasmin C; Mercatello A; Fosså SD; Symann M; Stoter G; Nagel G; Israel L
Eur J Cancer; 1991; 27(12):1583-9. PubMed ID: 1782066
[TBL] [Abstract][Full Text] [Related]
10. Treatment of advanced renal cell cancer with sequential intravenous recombinant interleukin-2 and subcutaneous alpha-interferon.
Besana C; Borri A; Bucci E; Citterio G; Di Lucca G; Fortis C; Matteucci P; Tognella S; Tresoldi M; Baiocchi C
Eur J Cancer; 1994; 30A(9):1292-8. PubMed ID: 7999416
[TBL] [Abstract][Full Text] [Related]
11. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects.
Budd GT; Osgood B; Barna B; Boyett JM; Finke J; Medendorp SV; Murthy S; Novak C; Sergi J; Tubbs R
Cancer Res; 1989 Nov; 49(22):6432-6. PubMed ID: 2804986
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
14. Weekly 24-hour continuous infusion interleukin-2 for metastatic melanoma and renal cell carcinoma: a phase I study.
Perez EA; Scudder SA; Meyers FA; Tanaka MS; Paradise C; Gandara DR
J Immunother (1991); 1991 Feb; 10(1):57-62. PubMed ID: 2012799
[TBL] [Abstract][Full Text] [Related]
15. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced renal cell carcinoma.
Lopez M; Carpano S; Cancrini A; Marcellini M; Del Medico P; Rinaldi M; Vici P; Paoletti G; Di Lauro L
Ann Oncol; 1993 Sep; 4(8):689-91. PubMed ID: 8241001
[TBL] [Abstract][Full Text] [Related]
18. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
19. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
[TBL] [Abstract][Full Text] [Related]
20. High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma.
Abrams JS; Rayner AA; Wiernik PH; Parkinson DR; Eisenberger M; Aronson FR; Gucalp R; Atkins MB; Hawkins MJ
J Natl Cancer Inst; 1990 Jul; 82(14):1202-6. PubMed ID: 2194036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
